35 completed. 35 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 35 | Completed 35 |
| Phase 2 | 14 | Completed 14 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR Secukinumab - Giant Cell Arteritis, Polymyalgia Rheumatica | Phase 1 | Completed | Novartis Pharmaceuticals | 65 | 2024-03-27 | 2026-04-01 |
| JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease Ruxolitinib - Kohlmeier Degos Disease With Neurologic Involvement, Kohlmeier-Degos Disease | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1 | 2023-09-28 | 2026-02-03 |
| The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects STSA-1002 subcutaneous injection - Antineutrophil Cytoplasmic Antibody Associated Vasculitis | Phase 1 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 20 | 2023-01-31 | 2023-05-26 |
| Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Glucocorticoids - ANCA-associated Vasculitis | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 93 | 2022-02-22 | 2025-08-07 |
| Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers Tocilizumab Prefilled Syringe - Rheumatoid Arthritis, Giant Cell Arteritis | Phase 1 | Completed | Syneos Health | 300 | 2021-05-31 | 2024-01-05 |
| A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants Avacopan, Moxifloxacin, Placebo for avacopan - Electrocardiography | Phase 1 | Completed | Amgen | 58 | 2019-11-08 | 2023-08-14 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA). Tocilizumab - Giant Cell Arteritis | Phase 1 | Completed | Hoffmann-La Roche | 24 | 2019-08-05 | 2021-12-22 |
| Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab Tocilizumab, Glucocorticoids - Giant Cell Arteritis | Phase 1 / Phase 2 | Completed | Insel Gruppe AG, University Hospital Bern | 18 | 2018-12-01 | 2021-06-22 |
| A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment Avacopan - Hepatic Impairment | Phase 1 | Completed | Amgen | 24 | 2018-04-17 | 2023-08-22 |
| A Study of CCX168 in Japanese and Caucasian Healthy Adult Males CCX168, Placebo - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 | Completed | Amgen | 80 | 2017-10-23 | 2023-08-14 |
| A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications CCX168, Midazolam, Celecoxib - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 | Completed | Amgen | 32 | 2016-01-14 | 2023-08-22 |
| A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168 CCX168 - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 | Completed | Amgen | 16 | 2015-12-03 | 2023-08-14 |
| Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Anakinra - Kawasaki Disease | Phase 1 / Phase 2 | Completed | University of California, San Diego | 22 | 2014-11-01 | 2024-03-04 |
| A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants [14C]CCX168 - Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 | Completed | Amgen | 6 | 2014-10-20 | 2023-08-22 |
| Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis triamcinolone acetonide (Triesence®) - Uveitis, Intermediate Uveitis | Phase 1 / Phase 2 | Completed | Clearside Biomedical, Inc. | 11 | 2013-02-01 | 2021-02-21 |
| Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Intravitreal Infliximab - Behçet's Disease, Uveitis | Phase 1 / Phase 2 | Completed | Cairo University | 20 | 2013-01-01 | 2015-12-03 |
| Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Atorvastatin - Kawasaki Disease | Phase 1 / Phase 2 | Completed | University of California, San Diego | 34 | 2012-07-01 | 2020-05-06 |
| Anakinra for Behcet s Disease Anakinra - Autoimmune Connective Tissue Disorder, Immune System Diseases | Phase 1 / Phase 2 | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 6 | 2011-09-01 | 2017-05-12 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants CCX168, Placebo - Vasculitis, Systemic Lupus Erythematosus (SLE) | Phase 1 | Completed | Amgen | 48 | 2009-12-21 | 2023-08-09 |
| Autologous Endothelial Progenitor Cells (EPCs) From Peripheral Blood in the Treatment of Critical Limb Ischemia Endothelial progenitor cells intramuscular implant - Critical Limb Ischemia | Phase 1 / Phase 2 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 8 | 2009-01-01 | 2012-06-14 |
Showing 20 of 35. Sign in to see all of them.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8) · Giant Cell Arteritis (6) · Granulomatosis with Polyangiitis (5) · Mucocutaneous Lymph Node Syndrome (4) · Vascular Diseases (4) · Cardiovascular Diseases (3) · Inflammation (3) · Lupus Erythematosus, Systemic (3) · Uveitis (3) · Behcet Syndrome (2) · Churg-Strauss Syndrome (2) · Uveitis, Posterior (2) · Arthritis, Rheumatoid (1) · Atherosclerosis (1)
Cardiovascular Diseases (32) · Skin and Connective Tissue Diseases (32) · Skin Diseases (31) · Vascular Diseases (31) · Skin Diseases, Vascular (30) · Immune System Diseases (25) · Autoimmune Diseases (23) · Systemic Vasculitis (15) · Hemic and Lymphatic Diseases (9) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (8) · Brain Diseases (8) · Central Nervous System Diseases (8) · Cerebrovascular Disorders (8) · Nervous System Diseases (8)
avacopan (6) · tocilizumab (3) · Glucocorticoids (2) · Interleukin 1 Receptor Antagonist Protein (2) · Mycophenolic Acid (2) · mepolizumab (2) · Abatacept (1) · Adrenal Cortex Hormones (1) · Atorvastatin (1) · BDB001 (1) · Celecoxib (1) · Cell- and Tissue-Based Therapy (1) · Cyclophosphamide (1) · Heparin (1) · Immunoglobulins, Intravenous (1)
Amgen (7) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · University of California, San Diego (3) · National Institutes of Health Clinical Center (CC) (2) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (2) · Brigham and Women's Hospital (1) · Cairo University (1) · Children's Hospital Medical Center, Cincinnati (1) · Clearside Biomedical, Inc. (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Gilead Sciences (1) · Hoffmann-La Roche (1) · Insel Gruppe AG, University Hospital Bern (1) · Lantheus Medical Imaging (1)
United States (25) · Switzerland (4) · Canada (2) · Italy (2) · Australia (1) · China (1) · Czechia (1) · France (1) · India (1) · Japan (1) · New Zealand (1) · Portugal (1) · Spain (1) · Taiwan (1)
Jane C Burns, MD (2) · Adriana H Tremoulet, MD (1) · Attilio Odero, Professor (1) · Carol A. Langford, MD, MHS (1) · Cornelia D Cudrici, M.D. (1) · Fernando C. Fervenza, M.D., Ph.D. (1) · Jane C Burns, M.D. (1) · Mahmoud Soliman, MD PhD (1) · Marc E. Rothenberg, MD (1) · Martin K Kankam, Doctor (1) · Michael Wechsler, MD (1) · Minghui Zhao, Postdoc (1) · Narinder Paul, FRCP C (1)
PMID 20093349, PMID 22129253, PMID 24323392, PMID 25858045, PMID 26526721, PMID 27080929, PMID 27923814, PMID 27980877, PMID 28335798, PMID 33950298, PMID 34117737, PMID 35659282, PMID 37287970, PMID 38287611, PMID 38973157, PMID 38993026, PMID 42532045
2018 (2), 2023 (1), U54AR057319 (1)